Pharmaceutical Industry Archives - IMAA – Institute for Mergers, Acquisitions, and Alliances

Deal Capsule: Transactions In Chemicals & Pharmaceuticals July 2016

November 29, 2021August 5, 2016 by Christopher Kummer

by KPMG
The number of completed deals remained high in both sectors in HY1 2016. While total deal value for pharmaceuticals decreased, chemicals witnessed a 40% increase in HY1 2016 versus HY1 2015. Pharmaceutical M&A was impacted by stock market volatility, while new US regulatory rules struck down the $160 billion Pfizer-Allergan merger. Oncology and dermatology were key areas of interest for big pharma, who were especially keen on acquiring biotech assets. […] Read more

Deal Capsule: Transactions In Chemicals & Pharmaceuticals April 2016

August 21, 2023April 20, 2016 by Christopher Kummer

by KPMG
While the number of completed pharma deals were slightly higher in Q1 2016 versus Q1 2015, deal value was far lower in the absence of any >$10 billion completions. Only one deal exceeded $5 billion in Q1 2016 (versus 8 in Q1 2015). Specialization continues to be a driving force in Q1 2016, especially in sectors such as OTC, rare diseases and oncology. Declines in transaction values were also witnessed in chemicals. Downstream specialty chemicals was the leading focus area, notably in applications, resins and agrochemicals. […] Read more

Pfizer, Allergan deal dead, what could be next?

November 29, 2021April 6, 2016 by Christopher Kummer

by CNBC
A $160 billion merger between Pfizer and Allergan lay in tatters Wednesday and left experts contemplating whether more deals could be hit by new tax rules issued by the U.S. Treasury. The deal, which would have allowed New York-based Pfizer to cut its tax bill by redomiciling to Ireland, has now been formally ended. Fresh rules issued Monday make it tougher for target companies to pass on their overseas registered address and in turn, beneficial tax rates. […] Read more

Approach To The Issues Of Leadership In The Processes Of Companies’ Acquisitions

June 24, 2022July 19, 2015 by Christopher Kummer

Table 2 Approach to the issues of leadership in the process of acquisition in the examined pharmaceutical companies

by Elsevier Ltd.
This paper presents the results of the research concerning five transactions in the pharmaceutical sector. The research aim was to diagnose an approach to the issues of leadership, which in the literature is often treated as a key success factor in the processes of acquisitions. The research showed that in the analyzed pharmaceutical companies which participated in the research little attention was paid to the issues of leadership. […] Read more

Firepower Fireworks: Focus, Scale And Growth Drive Explosive M&A

November 29, 2021January 1, 2015 by Christopher Kummer

by Ernst & Young
Record biopharma M&A exceeded US$200 billion in 2014, well over twice the average annual deal volume seen in the last decade, as companies used deal making to satisfy the strategic imperatives of increasing focus, scale and/or growth. A convergence of forces fueled the fireworks, including rising equity valuations, historically low interest rates and prodigious firepower. […] Read more

Pliva: A School for Hostile Takeovers

August 21, 2023July 7, 2006 by Michael Tierney

(Original: “Pliva: Škola neprijateljskog preuzimanja”); in: LiderPress
Ako Pliva bude prodana po 743 kune za dionicu ili više, ta će akvizicija u farmaciji biti zapamćena s postignutom najvećom razlikom između prvotne i konačne ponude […] Read more

Are you sure youwant to log out?

Are you sure you
want to log out?